Skip to contentpdufa.bio

ARV-393 Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

ARV-393 Phase is an Arvinas, Inc. program in B- and T-cell lymphomas (relapsed/refractory NHL). Its next catalyst is a Readout in Q4 2027.

ARVN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: B- and T-cell lymphomas (relapsed/refractory NHL). Sponsor: Arvinas, Inc. (ARVN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027ARVN

Questions

When is ARV-393 Phase's next FDA decision or readout?

The next tracked catalyst for ARV-393 Phase is a Readout in Q4 2027.

What happened at ARV-393 Phase's most recent FDA decision?

No FDA decision for ARV-393 Phase is in our archive yet.

What is ARV-393 Phase used for?

In our records ARV-393 Phase is under review or in development for B- and T-cell lymphomas (relapsed/refractory NHL).

Who makes ARV-393 Phase?

Arvinas, Inc. (ARVN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.